Project Grant R41AG090212
Award Date
9/15/24
Completion Date
5/31/25
Dollars Obligated
$1M
Federal Agency
National Institute on Aging
Awardee
Eydis Bio, Inc. (MWWCM7JMBCF1)
Federal Grant Program
93.866
Assistance Type
Project Grant
Place of Performance
North Carolina, USA
Similar Awards
This federal Project Grant award from the National Institute on Aging's Aging Research program (CFDA 93.866) provides $499,441 to Acepre, LLC to develop a novel brain-targeted delivery system for the compound N-acetylcysteine (TN-NAC) as a potential treatment for Alzheimer's disease (AD). The key objectives of this Phase I STTR study are to: 1) evaluate the toxicity and pharmacokinetic properties of TN-NAC in mice, and 2) test the therapeutic efficacy of TN-NAC in a 3xTG-AD mouse model of...
This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $500,000.00 to Alzarrok Bio LLC to develop a peptide-based multi-target drug for Alzheimer's disease (AD). The goal is to demonstrate the in vivo efficacy of the drug candidate, ALZ100, in inhibiting neuroinflammation and neurodegeneration in an AD mouse model. The project will first determine the therapeutic concentration of ALZ100 in the brain and then evaluate its effects on key...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) to Jillion Therapeutics Inc. aims to identify small molecule compounds that can bind to and modify the biological behavior of tau protein, which is implicated in Alzheimer's disease and other neurodegenerative "tauopathies". The $496,373 award, spanning September 2024 to August 2025, will utilize the company's DNA-encoded library (DEL) drug discovery platform to screen a large chemical...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) will fund the development of a novel Alzheimer's disease therapeutic using targeted nanoparticles. The $504,732 award to Aphios Corp, a minority-owned biotechnology company, will support two phases of research. In Phase I, the company will nanoencapsulate an anti-CCR5 drug in targeted and non-targeted nanoparticles, characterize the formulations, and evaluate their impact on in vitro models of brain...
This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $499,998.00 to Encue Inc., a small disadvantaged business located in Evanston, IL, to develop novel small molecule modulators of synaptic plasticity for the treatment of Alzheimer's disease (AD)-induced cognitive decline. The project aims to further develop the lead molecule JB2 as a therapeutic to reverse or delay the onset of cognitive dysfunction in AD by restoring normal expression...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) to Transchromix LLC provides $994,436 to develop novel brain-penetrant drugs that target the histone methyltransferase G9A for the treatment of Alzheimer's disease. The research aims to elucidate the noncanonical, translation regulatory function of G9A in Alzheimer's disease pathogenesis and evaluate the mechanism of action of a brain-penetrant G9A-targeted drug, MS1262, which has been shown to reverse...
The National Institute on Aging (NIA) awarded a $514,862 Project Grant (CFDA 93.866 - Aging Research) to Neuroindx, a for-profit, woman-owned small business, to develop an on-chip functional assay for identifying candidate microtubule-binding drugs to treat Alzheimer's Disease and related disorders (ADRDs). The goal of the project is to create an in vitro assay that can replicate key features of the neuronal microtubule microenvironment and use kinesin-based readouts to measure the ability of...
The federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) to Allyx Therapeutics Inc. in the amount of $3,357,206 supports the clinical evaluation of a novel drug compound, BMS-984923, for the treatment of Alzheimer's disease (AD). The funding will enable preclinical development, IND approval, and Phase 1 clinical trials to evaluate the safety and efficacy of this small molecule drug in improving synapse density, restoring hippocampal activity, and...
Tiaki Therapeutics Inc. was awarded a $1,099,720 cooperative agreement from the National Institute on Aging, part of the National Institutes of Health within the Department of Health and Human Services, to support research under the Aging Research program (CFDA 93.866). The award will fund the optimization of Tiaki's lead small molecule compounds that modulate sphingosine 1-phosphate receptor signaling to treat Alzheimer's disease by reducing neuroinflammation. Specifically, the funding will...
The National Institute on Aging (NIA) awarded a $349,605 Project Grant (CFDA 93.866 - Aging Research) to Stress Therapeutics, Inc. on June 1, 2025. The grant will fund the lead optimization of a novel therapeutic candidate for the long-term management of hyperactivity in the hypothalamic-pituitary-adrenal (HPA) axis, a key pathogenic driver of Alzheimer's disease (AD) and other degenerative conditions. The project aims to advance the development of this first-in-class treatment to normalize...